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LETTERS TO THE EDITOR
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To the Editor: Bokenkamp et al reported that cystatin patients. Kidney Int 60:1561–1564, 2001
3. Risch L, Herklotz R, Blomberg A, Huber AR: Effects of immuno-C underestimates glomerular filtration rate (GFR) in
suppressive glucocorticoid therapy on serum cystatin C levels ofrenal transplant patients [1]. As a mechanism for this renal transplant patients. Clin Chem, in press.
finding, they proposed that cystatin C would form macro- 4. Plebnani M, Dall’Amico R, Mussap M, et al: Is serum cystatin C a
sensitive marker of glomerular filtration rate (GFR)? A preliminarymolecules consisting of cystatin C complexed to immu-
study on renal transplant patients. Ren Fail 20:303–309, 1998noglobins. As a consequence, cystatin C would not be 5. Risch L, Blumberg A, Huber A: Rapid and accurate assessment
freely filtered and thus would accumulate in serum. In of glomerular filtration rate in patients with renal transplants using
serum cystatin C. Nephrol Dial Transplant 14:1991–1996, 1999another interesting paper, Hermida et al test this hypoth-
esis by measuring the postulated complexes [2]. Their
negative findings make macromolecule formation an un-
likely explanation for increased cystatin C in trans-
planted patients.
More recent results now indicate that glucocorticoid
drugs, frequently administered in transplanted patients,
Continuous renalrepresent this yet unknown “cystatin C increasing fac-
tor.” A case-control study in kidney transplant recipients
observed that glucocorticoid administration in a dose- replacement therapy versus
dependent manner leads to increased cystatin C concen-
trations [3]. These findings do not preclude the use of intermittent hemodialysis in
cystatin C in detecting impaired renal function, since this
study [3] and others [4, 5] revealed cystatin C to be acute renal failure
significantly more accurate in detecting impaired renal
function in kidney transplant recipients receiving gluco-
To the Editor: I commend Mehta et al [1] for theircorticoids. Moreover, the need for specific reference
recent article in Kidney International. They confirmedranges in patients with glucocorticoid therapy is clearly
that severity of illness, but not the modality of renal re-demonstrated.
placement therapy (RRT), is the major determinant ofIt must be emphasized that glucocorticoid administa-
mortality, and that sicker patients tend to get continuoustion so far has not been included into data analysis of
renal replacement therapy (CRRT).studies evaluating cystatin C as a marker of impaired
Their optimistic expectation of 28.5% mortality dif-renal function. Depending on the investigated collective,
ference, and 50% observed mortality (versus 70% pre-a bias in data interpretation therefore is likely to have
dicted), hampers their power. Choosing a smaller differ-occurred. In summary, to avoid underestimation of glo-
ence would have increased the sample size and wouldmerular filtration rate in clinical routine settings as well
have avoided the possibility of missing a smaller differ-as in future clinical studies, it is important to take gluco-
ence. It was unfair to exclude hypotensive patients whocorticoid medication in account when interpreting cy-
could have benefited more by CRRT.statin C levels in renal transplant patients, and, presum-
As solute clearance may influence the outcome, theably, in other patient collectives.
relevance of their results to currently proposed higher
Lorenz Risch and Andreas R. Huber standards [2, 3] becomes questionable.
Aarau, Switzerland Authors often use citrate-based regional anticoagula-
tion, requiring dialysate modification, which can affectCorrespondence to Professor Andreas R. Huber, M.D., Head, Zen-
trum fu¨r Labormedizin, Kantonsspital, 5001 Aarau, Switzerland. the cost for CRRT. Filters are becoming less expensive,
E-mail: andreas.huber@ksa.ch and newer machines require fewer infusion pumps.
Interestingly, 21% of patients (11% died, renal func-
tion improved in 10%) either did not receive or received
a short course of RRT, underscoring the difficulty of ap- 2002 by the International Society of Nephrology
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propriate timing and indications for beginning RRT. severity of illness and its effect on outcomes should pro-
mote a change in our paradigms for the appropriateCRRT achieved a higher rate of renal recovery. Intermit-
tent hemodialysis (IHD) provided inadequate azotemia selection of dialysis modality and its application for renal
control despite 5.2 treatments/week and failed to achieve support rather than replacement [3]. Our results also sup-
fluid goals in 28.8%. port the need for further research to establish standards
CRRT may be more feasible and better tolerated in for timing, indications, dose of dialysis, and then for an
unstable, highly catabolic/hypervolemic patients, and in individualized approach for management of acute renal
those with liver failure. IHD is cheaper, associated with failure before embarking on future randomized controlled
fewer bleeding complications, and can be used in patients trials. The Acute Dialysis Quality Initiative (ADQI) is an
who tolerate it (adjusting solute clearance). The role of initial attempt, which we hope will serve as a starting
hemofiltration in sepsis [2, 3] requires more data and point for future research and development of practice
identification of precise mechanism. guidelines in this field [4].
Mehta et al have contributed to the debate of CRRT
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We should use common sense and tailor the therapy indi- Correspondence to Ravindra L. Mehta, M.D., Department of Internal
Medicine, Nephrology Division, University of California, San Diego,vidually, instead of pursuing more randomized con-
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E-mail: rmehta@ucsd.edu
Bulent Cuhaci
REFERENCESPhiladelphia, PA
1. Mehta RL, McDonald B, Gabbai FB, et al: A randomized clinical
Correspondence to Bulent Cuhaci, M.D., MCP Hospital, Suite 4271, trial of continuous versus intermittent dialysis for acute renal failure.
3300 Henry Avenue, Philadelphia, PA 19129, USA. Kidney Int 60:1154–1163, 2001
E-mail: bulentcuhaci@yahoo.com 2. Mehta RL, Letteri JM: Current status of renal replacement therapy
for acute renal failure. A survey of US nephrologists. The National
Kidney Foundation Council on Dialysis. Am J Nephrol 19(3):377–REFERENCES
382, 1999
1. Mehta RL, McDonald B, Gabbai FB, et al: A randomized clinical 3. Mehta RL: Indications for dialysis in the ICU: Renal replacement
trial of continuous versus intermittent dialysis for acute renal failure. vs. renal support. Blood Purification 19(2):227–232, 2001
Kidney Int 60:1154–1163, 2001 4. Ronco C, Kellum J, Mehta RL: Acute dialysis quality initiative.
2. Ronco C, Bellomo R, Homel P, et al: Effects of different doses in Blood Purification 19(2):222–226, 2001
continuous veno-venous haemofiltration on outcomes of acute renal
failure: a prospective randomized trial. Lancet 356:26–30, 2000
3. Honore PM, Jamez J, Wauthier M, et al: Prospective evaluation
of short-term, high-volume isovolemic hemofiltration on the hemo-
dynamic course and outcome in patients with intractable circula-
tory failure resulting from septic shock. Crit Care Med 28:3581–
3587, 2000
4. Kumar VA, Craig M, Depner TA, et al: Extended daily dialysis:
A new approach to renal replacement for acute renal failure in the Fragmentation of filtered
intensive care unit. Am J Kidney Dis 36:294–300, 2000
proteins and implications forReply from the Author
We agree with Dr. Cuhaci that underlying severity of glomerular protein sieving inillness is a strong determinant of outcome from acute
renal failure requiring dialysis. As discussed in our article Fanconi syndrome
[1], the study was powered for an effect size of 20%
reduction in mortality (from 70% to 50%) and we did
not include hypotensive patients to avoid biasing the To the Editor: The calculations of glomerular sieving
coefficients in Fanconi syndrome by immunoassay [1]study in favor of continuous renal replacement therapy
(CRRT). We did not standardize timing and indication have not considered the effects of the relatively large
quantities of protein fragments [2] that arise by degrada-or dose of dialysis as these factors are not well defined
even today and were even less appreciated when the tion of filtered protein during renal passage [3, 4]. The
fragments do not arise in plasma of non-filtered kidneysstudy was initiated. Despite its limitations, we believe
that our study is still relevant to modern-day practice. nor are they at sufficient concentration in the circulation
to account for the matieral in urine [4]. Fragments areIt highlights the importance of standardizing an ap-
proach for dialysis in acute renal failure as there is wide not detected by immunoassays [5]. It is clear that any
estimation of protein glomerular sieving coefficient hasvariation in the timing and indications for dialysis and
choice of modality [2]. Recognition of the underlying to take into account these fragments. Furthermore, esti-
